Simplify Logo

Full-Time

Principal Scientist

Translational Sciences

Confirmed live in the last 24 hours

Arcellx

Arcellx

51-200 employees

Develops cell therapies for cancer, autoimmune diseases

Biotechnology
Healthcare

Compensation Overview

$160k - $175kAnnually

+ Bonus + Equity Grant

Senior

North Bethesda, MD, USA

Relocation assistance offered if required.

Category
Genomics
Biology Lab & Research
Biology & Biotech
Requirements
  • PhD, MD or MD/PhD degree in a relevant scientific field (e.g., cancer biology, immunology, hematology), with 8+ years post-degree experience, inclusive of 3+ years of experience in a formalized Translational Science/Medicine role within a large pharma/biotech company is required.
  • Understanding of early or late-stage drug and translational development process, including clinical trial experience in industry or academia.
  • In-depth understanding of myeloid disease biology (e.g., AML, MDS), knowledge of clinical landscape, evolving therapy, and competitive scenarios.
  • Demonstrated record of research accomplishment as evidenced by publications or major contributions to drug development milestones.
  • Highly developed problem solving and risk management abilities.
  • Strategic thinker with proven leadership skills and/or prior project team leadership roles.
  • Proficiency in distilling complex issues and clearly articulating viable paths forward.
Responsibilities
  • Lead implementation of clinical biomarker strategy to enable target engagement characterization, PK/PD indication of biologic activity and assessment of patient response.
  • Serve as a key contributor to integrate, influence, and execute on translational/biomarker plans.
  • Communicate translational updates and conduct strategic discussions for key programs with diverse audiences, including senior management.
  • Understand key cancer pathway interactions and feedback mechanisms in clinical samples to inform ongoing clinical trials.
  • Define novel mechanisms of resistance by studying samples at relapse.
  • Contribute relevant scientific expertise, strategy, and experimentally-derived insights as a member of multidisciplinary project teams working to drive the preclinical to clinical translation of pipeline assets.
  • Plan, design, and execute IND-enabling pharmacology, pharmacokinetic and toxicology studies by applying knowledge of disease-associated pathways, preclinical models, and drug development.
  • Contribute to the preparation of IND applications and other regulatory documents, as appropriate, leveraging up-to-date knowledge of FDA cellular therapy guidance.
  • Establish and cultivate relationships with external CRO collaborators for basic and translational research.
  • Maintain a current and comprehensive understanding of disease biology, treatment paradigm, and competitive landscape for key programs.

Arcellx develops innovative cell therapies for cancer and autoimmune diseases, leveraging their novel D-Domain technology and transformative ddCAR and ARC-SparX platforms to enhance cell therapy.

Company Stage

N/A

Total Funding

$736M

Headquarters

Gaithersburg, Maryland

Founded

2014

Growth & Insights
Headcount

6 month growth

24%

1 year growth

26%

2 year growth

78%
Simplify Jobs

Simplify's Take

What believers are saying

  • The Phase 3 iMMagine-3 trial for anito-cel could significantly boost Arcellx's market position if successful.
  • Recent robust long-term responses from the Phase 1 expansion trial of anito-cel indicate promising efficacy and safety, potentially leading to FDA approval.
  • The $285M equity investment and upfront cash from Kite provide substantial financial backing for Arcellx's ongoing and future projects.

What critics are saying

  • The competitive landscape for CAR T therapies is intense, with established players like Abecma and Carvykti posing significant challenges.
  • Regulatory hurdles, such as the recent FDA partial hold, could delay product development and market entry.

What makes Arcellx unique

  • Arcellx's anitocabtagene autoleucel (anito-cel) is the first BCMA CAR T therapy for multiple myeloma utilizing a novel D-Domain binder, setting it apart from existing treatments.
  • The company's strategic partnership with Kite, a Gilead Company, enhances its research capabilities and market reach, distinguishing it from smaller biotech firms.
  • Arcellx's focus on innovative immunotherapies for cancer and other incurable diseases positions it uniquely in the biotech landscape.